G. Bureau
Institut Jules Bordet · 55 works · 1,750 citations · h-index 19
Top works
- Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
- Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
- Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
- A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
- Prognostic factors for patients with small cell lung carcinoma
- Endpoints for multimodal clinical trials in Stage III non-small cell lung cancer (NSCLC): a consensus report
- Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer
- Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
- Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.
- Pretreatment minimal staging for non-small cell lung cancers: a consensus report
- Trisomy 7 in a lung carcinoid tumor: Precocious index of malignant transformation?
- Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer
- Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.
- Monoclonal Immunoradiometric Assay and Polyclonal Radioimmunoassay Compared for Measuring Neuron-Specific Enolase in Patients with Lung Cancer
- A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancer
- A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil
- A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: A preliminary report
- Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC)
- A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer
- A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer